The roles and implications of RNA m6A modification in cancer

X Deng, Y Qing, D Horne, H Huang… - Nature Reviews Clinical …, 2023 - nature.com
Abstract N 6-Methyladenosine (m6A), the most prevalent internal modification in eukaryotic
mRNA, has been extensively and increasingly studied over the past decade. Dysregulation …

[HTML][HTML] Insights into N6-methyladenosine and programmed cell death in cancer

L Liu, H Li, D Hu, Y Wang, W Shao, J Zhong, S Yang… - Molecular cancer, 2022 - Springer
Abstract N6-methyladenosine (m6A) methylation, the most common form of internal RNA
modification in eukaryotes, has gained increasing attention and become a hot research topic …

[HTML][HTML] The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia

H Weng, F Huang, Z Yu, Z Chen, E Prince, Y Kang… - Cancer Cell, 2022 - cell.com
Summary N 6-Methyladenosine (m 6 A) modification and its modulators play critical roles
and show promise as therapeutic targets in human cancers, including acute myeloid …

FTO mediates LINE1 m6A demethylation and chromatin regulation in mESCs and mouse development

J Wei, X Yu, L Yang, X Liu, B Gao, B Huang, X Dou… - Science, 2022 - science.org
N 6-methyladenosine (m6A) is the most abundant internal modification on mammalian
messenger RNA. It is installed by a writer complex and can be reversed by erasers such as …

[HTML][HTML] Role of m6A writers, erasers and readers in cancer

Z Fang, W Mei, C Qu, J Lu, L Shang, F Cao… - … Hematology & Oncology, 2022 - Springer
Abstract The N (6)-methyladenosine (m6A) modification is the most pervasive modification of
human RNAs. In recent years, an increasing number of studies have suggested that m6A …

FTO in cancer: functions, molecular mechanisms, and therapeutic implications

Y Li, R Su, X Deng, Y Chen, J Chen - Trends in cancer, 2022 - cell.com
N 6-methyladenosine (m 6 A) is the most abundant internal modification in mRNA that
affects RNA processing, stability, and translation. Discovered as the first RNA m 6 A …

METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism

L Han, L Dong, K Leung, Z Zhao, Y Li, L Gao, Z Chen… - Cell Stem Cell, 2023 - cell.com
Summary N 6-methyladenosine (m 6 A), the most prevalent internal modification in
mammalian mRNAs, is involved in many pathological processes. METTL16 is a recently …

[HTML][HTML] YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of …

RC Chai, YZ Chang, X Chang, B Pang, SY An… - Journal of hematology & …, 2021 - Springer
Background The prognosis for diffuse gliomas is very poor and the mechanism underlying
their malignant progression remains unclear. Here, we aimed to elucidate the role and …

Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities

T Ge, X Gu, R Jia, S Ge, P Chai… - Cancer …, 2022 - Wiley Online Library
Reversible, spatial, and temporal regulation of metabolic reprogramming and epigenetic
homeostasis are prominent hallmarks of carcinogenesis. Cancer cells reprogram their …

[HTML][HTML] Biological and pharmacological roles of m6A modifications in cancer drug resistance

Z Liu, H Zou, Q Dang, H Xu, L Liu, Y Zhang, J Lv, H Li… - Molecular Cancer, 2022 - Springer
Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant
cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological …